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cu.2012.Abstract A simple, rapid, sensitive and accurate HPLC–UV detection method was developed and
validated for the determination of isotretinoin in human plasma. The method involves protein pre-
cipitation of plasma by acetonitrile using nifedipine as the internal standard (IS). Chromatographic
separation was achieved on Agilent C18 column using an acetonitrile: aqueous 0.5% glacial acetic
acid (70:30, v/v) mobile phase. Isotretinoin in the eluent was monitored at 350 nm. Inter-assay of
the coefﬁcient of variations (CV%) over the range of plasma calibration curves (0.02–0.60 lg/ml)
ranged from 2.32% to 6.49% with good correlation coefﬁcient (R2 = 0.999). The average recovery
of the extraction procedure was 99.128%. The LLOD and LLOQ are 0.007 and 0.02 lg/ml, respec-
tively. This method was applied for pharmacokinetic study and the results indicated that this
method is suitable for pharmacokinetic and bioavailability studies.
ª 2012 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Isotretinoin (INN) (13 cis)-retinoic acid, Fig. 1.1 Its medication
is used for the treatment of severe acne and a number of can-
cers and rosacea. It was ﬁrst developed to be used as a chemo-
therapy medication for the treatment of brain cancer and
pancreatic cancer.2,3 Isotretinoin contains a carboxylic acid
moiety and is a potentially teratogenic compound with re-2716868.
m (N.F. Abo-Talib).
aculty of Pharmacy, Cairo
g by Elsevier
, Cairo University. Production and
09.001ported terminal elimination half-lives in the order of 6–22.4,5
There is also interest in the prophylactic and therapeutic effects
of 13-cis-RA in in vitro and in vivo carcinogenetic studies6,
pigmentary disorders and photoaging.7
Several chromatographic methods have been published for
the quantiﬁcation of isotretinoin in a biological matrix (plasma
or serum) and brain tissue. Some of these methods include
high-performance liquid chromatography with ultra-violet
detection8–19 and others are high-performance liquid chroma-
tography with mass spectrometric detection.19–21 Most of these
methods depend on lengthy sample preparation schemes
including extractions with an organic solvent, evaporation of
solvent and reconstitution prior to HPLC analysis or require
expensive instruments such as LC–MS–MS or need column
switching techniques (online solid-phase extraction). The pur-
pose of this study was to establish a simple, rapid, sensitive and
validated method for the determination of isotretinoin usinghosting by Elsevier B.V.Open access under CC BY-NC-ND license.
Figure 1 Chemical structure of isotretinoin (molecular formula:
C20H28 O2).
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application in pharmacokinetic study.
2. Experimental procedures
2.1. Chemicals and reagents
Isotretinoin working standard (99.9%) kindly provided by
Medizen Co. (Egypt). Nifedipine (IS, 99.8%) was obtained
from Sigma–Aldrich Co (UK). HPLC grade acetonitrile was
purchased from Merck (Darmstadt, Germany). Human plas-
ma was supplied by VACSERA, Egypt. Glacial acetic acid
was purchased from Loba Chemie (India). Water was obtained
from a Milli-Q water puriﬁcation system (Millipore Co,
France). The mobile phase component was ﬁltered through a
0.45 lm Whatman membrane ﬁlter prior to its use.
2.2. Instruments and chromatographic conditions
Liquid chromatographic separation with UV detection was
performed on a Waters chromatographic system (Milford,
USA) equipped with pump controlled by Waters 610 control-
ler, Waters 717 autosampler injector, and Waters 486 variable
wavelength UV detector. The drug analysis data were acquired
and processed using Empower software operated by Pentium
III (450 MHz) processor (Lenovo, UK). The mobile phase
consisted of a mixture of acetonitrile and 0.5% glacial acetic
acid (70:30, v/v) pumped at ﬂow rate of 1.5 ml/min. through
the Agilent Eclipse XDB C185 lm (150 · 4.0 mm, id) column
at ambient temperature with a guard column C18 5 lm
100 A˚. Peaks were monitored by a UV detector adjusted at
350 nm. Quantiﬁcation of isotretinoin was obtained by plot-
ting isotretinoin to internal standard peak area ratios as a
function of concentrations.
2.3. Calibration standards
Stock solutions of each of the isotretinoin and nifedipine (I.S)
samples were prepared in acetonitrile at a concentration of
100.00 lg/ml and stored at 4 C. Handling and analysis of all
samples were performed under diffused light conditions (pre-
pared away from light by using opaque glasses and aluminum
foil). Evaluations of the assay were performed by six point cal-
ibration curves made by serial dilution of the stock solution of
the drug at the nominal concentration range of 0.02–0.60 lg/
ml of isotretinoin in human plasma. Slope and intercept of
the calibration lines were determined.
2.4. Sample preparation
To each 400 ll of human plasma spiked with drug and I.S
(50 ll from 100.00 lg/ml), 1.5 ml of acetonitrile was addedfor deproteinization. The tube was capped and the contents
were vortexed for 30 s. and centrifuged for 10 min at
3500 rpm. The supernatant (200 ll) was injected into the
HPLC system.
2.5. Method validation
Evaluation of the reversed-phase liquid chromatography meth-
ods was based mainly on proportionality (linearity assay), pre-
cision and accuracy.22This method was developed and
validated as per FDA guidelines.23
2.5.1. Selectivity
The interference by the endogenous compound was assessed by
comparing the chromatograms obtained from the samples con-
taining isotretinoin and the internal standard with those ob-
tained from the blank samples.
2.5.2. Accuracy, precision and recovery
The intra-day precision of the assay was assessed by calculat-
ing the coefﬁcients of variation (CV%) of the samples in six
replicates and the inter-day precision was determined through
the analysis of the samples on three consecutive days. Accu-
racy was determined by comparing the calculated concentra-
tions to known concentrations with calibration curves.
The recovery of an analyte in an assay is the detector re-
sponse obtained from an amount of the analyte added to
and extracted from the biological matrix, compared to the
detector response obtained for the true concentration of the
pure authentic standard.
2.5.3. Calibration/standard curve
2.5.3.1. Linearity. The linearity of the calibration curve for iso-
tretinoin was assessed in the range of 0.02–0.60 lg/ml in the
plasma samples. The straight line regression was presented
with its correlation coefﬁcient.
2.5.3.2. Lower Limit of quantiﬁcation (LLOQ). It is deﬁned as
the lowest concentration of the analyte that can be determined
with acceptable precision and accuracy under the stated exper-
imental conditions.
It is determined as the concentrations with a signal-to-noise
ratio of 10:1, by comparing test results from samples with
known concentrations of the analyte to blank samples. Each
concentration standard should meet the following acceptable
criteria: a precision of 20% and accuracy of 80–120%. The
LLOQ was 0.02 lg/ml for isotretinoin in 18 standard calibra-
tion curves.
2.5.4. Stability
Low, medium and high quality control samples (n= 6), corre-
sponding to 0.05, 0.20 and 0.60 lg/ml were retrieved from the
deep freezer after three freeze–thaw cycles according to the
clinical protocols. Samples were frozen at 80 C in three cy-
cles of 24, 48, and 36 h. In addition, the long-term stability of
isotretinoin in quality control samples was also evaluated by
analysis after 55 days of storage at 80 C. Autosampler sta-
bility was studied following a 24 h-storage period in the auto-
sampler tray. Bench top stability was studied for a 6 h period.
Stability samples were processed and extracted along with the
freshly spiked calibration curve standards. The precision and
Figure 2 Chromatograms of (A) blank human plasma; (B) blank human serum spiked with isotretinoin (0.60 lg/ml) and nifedipine
(12.50 lg/ml) and (C) plasma sample obtained from volunteers 3 h after oral administration of Isotretinoin capsules (2 capsules of 20 mg/
capsule).
Table 1 Precision and accuracy of standard calibration curves









0.020 0.019 0.0004 2.11 95.00
0.050 0.046 0.0020 4.35 92.00
0.100 0.093 0.0030 3.23 93.00
0.200 0.201 0.0020 1.00 100.50
0.400 0.396 0.0050 1.26 99.00
0.600 0.606 0.0060 0.99 101.00
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±15%, respectively, of their nominal concentrations.
2.6. Clinical protocol
This method was applied in the analysis of plasma samples
after the administration of a single dose of two capsules of iso-
tretinoin 20 mg (Isotretinoin capsule) to healthy male volun-
teers. The study protocol was approved by the Ethics
Committee of Bioavailability Studies (NODCAR).The age of
6 volunteers ranged from 29 to 38 years, and the subjects
had a body weight ranging from 58 to 71 kg. All subjects gave
their written informed consent. The study was conducted in
accordance with the provisions of the Declaration of Helsinki.
After an overnight fast period volunteers received a single dose
of two capsules of isotretinoin 20 mg (Isotretinoin capsule)
with 200 ml of water. Blood samples (3 ml) from a suitable
antecubital vein were collected into heparin-containing tubes
immediately before dose (0.0) and at 1, 1.5, 2.0, 2.5, 3.0, 3.5,
4.0, 6.0, 8.0, 10.0 and 12.0 h post dosing. The blood sampleswere centrifuged at 3000 rpm for 5 min at room temperature
and the plasma was removed and stored at 80 C until as-
sayed for its isotretinoin content. All samples from a single vol-
Table 2 Precision and accuracy of standard calibration curves









0.020 0.019 0.0008 4.21 95.00
0.050 0.048 0.0020 4.17 96.00
0.100 0.099 0.0080 8.08 99.00
0.200 0.202 0.0040 1.98 101.00
0.400 0.398 0.0100 2.51 99.50
0.600 0.600 0.0180 3.00 100.00
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assay variations.
2.7. Pharmacokinetic analysis
Pharmacokinetic parameters from the human plasma samples
were calculated by a noncompartmental statistics model using
MINITAB Software Release 13.1.
Blood samples were taken for a period of 3 to 5 times the
terminal elimination half-life (t1/2) and it was considered as
the area under the concentration–time curve (AUC) ratio high-
er than 80% as per FDA guidelines.24,25
The ﬁrst-order terminal elimination rate constant (Kel) was
estimated by linear regression from the points describing the
elimination phase on a log-linear plot. The maximum observed
plasma concentration (Cmax) and the time taken to achieve this
maximum level (Tmax) were obtained directly from the curves.
The areas under the curve for isotretinoin plasma concentra-
tion versus time for 0–12 h (AUC0-12 h) were calculated by
applying the linear trapezoidal method. The extrapolation of
this area to inﬁnity (AUC0-inf) was done by adding the value
C12/Kel to the calculated AUC0-12 where C12 is the isotretinoin
plasma concentration at 12 h and Kel is the ﬁrst-order terminal
elimination rate constant.
3. Results and discussion
Owing to the photolability and sensitivity to heat and oxida-
tion of the retinoids, extreme precautions to protect isotreti-
noin from white light and to minimize exposure to oxygen
need to be taken when handling isotretinoin and the respective
solution.
The present study describes a simple, sensitive, accurate and
reproducible HPLC method for the determination of isotreti-
noin in human plasma. This method has several advantages
over the previously reported methods. Sample preparation,Table 3 Data showing the stability of isotretinoin in human plasm
Short-term stability (6 h, room temperature)
Freeze and thaw stability (3 cycles,80 C-room temperature)
Long-term stability (55 days,80 C)
Auto sampler stability (24 h, 4 C)in this method, is simpler as it involves only one step of depro-
teinization and requires a relatively small volume of plasma
(0.4 ml). In contrast, the previous methods are characterized
by lengthy sample preparation schemes including extractions
with an organic solvent, evaporation of solvent and reconstitu-
tion prior to HPLC analysis.9–11,16,17,20,21 Lyophilization of the
sample before extraction is required in other methods.8 The
use of HPLC–UV with column switching technique (online so-
lid-phase extraction) appeared to be the most promising.12,14,15
However, a complicated processing technique may limit its
wide application. Moreover the very low quantiﬁcation limit
obtained with a UV detector allowed us to avoid using ﬂuori-
metric or mass spectrophotometric detection19–21, which re-
quires more expensive equipment and makes our method
particularly useful for pharmacokinetic studies.
Different ratios of the mobile phase were tried and this ra-
tio was the suitable one. System suitability testing of the HPLC
method gave good resolution (R) = 10.867; relative retention
time (a) = 24.83; column capacity (K) = 10.4 and tailing fac-
tor (T) = 1.2. Under the chromatographic conditions de-
scribed, isotretinoin and nifedipine (IS) peaks are well
resolved. Fig. 2 shows typical chromatograms of blank plasma
in comparison to plasma spiked with drug and the internal
standard and the plasma sample obtained at 3 h from volun-
teers who received a single oral dose. The retention times of
the internal standard and isotretinoin were 1.3 min and
10.8 min, respectively. No endogenous compounds appear at
the retention time of isotretinoin or of the IS to interfere with
their peaks. The base line was relatively free from drift. Six
concentrations deﬁned the calibration curves. A calibration
curve was obtained by plotting the peak-area ratio (drug/IS)
against the concentration of isotretinoin in plasma. The linear-
ity of the calibration curves (n= 18) was veriﬁed from 0.02 to
0.60 lg/ml and the corresponding regression equation was
(y= 1.051x  0.008, r2 = 0.999), where y is the peak area ra-
tio of isotretinoin to nifedipine, x is the concentration of iso-
tretinoin (lg/ml) in plasma and r is the correlation coefﬁcient.
Intra-day precision (CV%) and accuracy were determined
with six calibration curves of six points of concentration (anal-
ysis in the same day) with the range of 0.99–4.35% and 92.00–
101.00, respectively (Table 1). Inter-day assay precision and
the accuracy of standard curves were determined by comparing
the peak area ratio of 6 standard curves prepared and injected
on 3 different days with the ranges of 1.98–8.08% and 95.00–
101.00, respectively (Table 2).
The extraction recovery determined for isotretinoin was
shown to be consistent, precise and reproducible. The average
recovery was 99.128% which is acceptable for the routine mea-
surement of isotretinoin.
Table 3 summarizes the freeze and thaw stability, short-
term stability, long-term stability and auto sampler stabilitya at different QC levels (n= 6).
Accuracy (mean ± CV%)
0.05 lg/ml 0.20 lg/ml 0.60 lg/ml
108.27 ± 7.40 89.42 ± 5.04 88.57 ± 8.04
107.72 ± 4.56 89.41 ± 6.10 90.85 ± 6.93
105.35 ± 5.92 101.48 ± 3.62 99.47 ± 3.61
101.10 ± 4.52 99.87 ± 6.52 98.38 ± 4.25
Figure 3 Mean drug plasma concentration–time curve of isotretinoin from 6 volunteers after oral administration of Isotretinoin capsule
(2 capsules of 20 mg/capsule).
Table 4 Pharmacokinetic parameters required for assessment
of Isotretinoin bioavailability.
Parameters Mean
Cmax (lg h/ml) 0.434 ± 0.033
tmax (h) 1.75
AUC0-12 (lg h/ml) 2.480 ± 0.014
AUC0-inf (lg h/ml) 3.097 ± 0.393
t1/2 (h) 4.604 ± 1.57
MRT (h) 7.703 ± 2.269
Kel (h) 0.1599 + 0.054
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behavior during these tests and there were no stability-related
problems during the routine analysis of samples for the bio-
availability study.
The method described here was successfully applied to
pharmacokinetic study of isotretinoin in healthy human volun-
teers. General adverse reactions were not observed with any
volunteer. Following oral administrations, plasma concentra-
tion–time curves of isotretinoin best ﬁt a non-compartment
in all subjects. Plasma concentration–time curves are shown
in Fig. 3. The pharmacokinetic parameters estimated are
shown in Table 4.
4. Conclusion
A simple HPLC–UV method with good accuracy, precision
and low detection limit was developed for the determination
of isotretinoin in human plasma samples. Lyophilization of
the sample before extraction or the use of expensive equip-
ments as LC/MS is not necessary in the present work and thus
the method is much faster and economical. Ultimately, the val-
idated HPLC method employed here exhibited acceptable pre-
cision and adequate sensitivity for the quantiﬁcation ofisotretinoin in human plasma samples resulting from the clin-
ical pharmacokinetic and bioavailability studies. The median
Tmax, Cmax and AUC values were similar to those reported
in the literature.4,5
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